ONCY
Oncolytics Biotech, Inc. Common SharesstockNASDAQ
oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics' clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.41 | 2026-11-11 | +4.50% | 0.730 |
| 1M | 0.50 | 2026-10-19 | -13.34% | -0.304 |
| 3M | 0.84 | 2026-08-18 | -49.09% | -0.020 |
| 6M | 0.80 | 2026-05-18 | -46.24% | 0.653 |
| 1Y | 1.03 | 2025-11-18 | -58.24% | 1.233 |
| 2Y | 1.00 | 2024-11-18 | -56.77% | — |
| 5Y | 1.75 | 2021-11-18 | -75.42% | 0.917 |
Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY) stock price today is $0.43, and today's volume is 2,185,489. ONCY is up 12.444% today. The 30 day average volume is 1.30M. ONCY market cap is $58.55M with 136.14M shares outstanding.